20 hrs ago
EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate understanding on how best to treat these older cancer patients.
Thu Jun 13, 2013
ImmunoGen's Management Presents at Goldman Sachs 34th Annual Global...
Good morning everyone and thank you for attending our annual global healthcare conference.
Certain Cancer Drug Elevates the Risk of Heart Failure
The risk of heart failure is alarmingly high in older women with breast cancer. And, according to Yale University researchers, if those women take one commonly prescribed drug, the risk is even higher.
Mon Jun 10, 2013
Early Data From First Human Study Suggests Radiation-Antibody Combination Is Safe
BIRMINGHAM, Ala. - An experimental treatment that combines a cell-killing radioactive particle with an antibody that homes in on cancer cells is safe in the treatment of cancers spreading through patients' abdomens, according to data from a first-in-human study presented today at the Society of Nuclear Medicine and Molecular Imaging annual meeting ... (more)
Sun Jun 09, 2013
Somatic Mutation Profiling and Associations With Prognosis and...
BACKGROUND: Certain somatic alterations in breast cancer can define prognosis and response to therapy.
Sun Jun 02, 2013
Novartis pivotal Phase III trial shows AfinitorA significantly...
The findings showed that adding everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine significantly extended progression-free survival when compared to treatment with placebo plus trastuzumab and vinorelbine, meeting the study's primary endpoint .
Tue May 28, 2013
Novartis highlights new findings in advancing care for patients with...
Novartis will present new findings in the treatment of advanced cancers and other diseases with 170 abstracts at two prominent medical meetings.
Sat May 25, 2013
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 ...
Cell proliferation , Vol. 40, No. 4. , pp. 488-507, doi:10.1111/j.1365-2184.2007.00449.x The potential of epidermal growth factor receptor - and Her2-targeted antibodies Cetuximab, Pertuzumab and Trastuzumab, used in combination to inhibit cell proliferation of breast cancer cells in vitro, has not been extensively investigated.
Fri May 24, 2013
beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
INTRODUCTION:The overexpression of human epidermal growth factor receptor -2 in 20% of human breast cancers and its association with aggressive growth has led to widespread use of HER2-targeted therapies, such as trastuzumab and lapatinib .